News
Parnell Acquires Noble Pharma LLC, Expanding U.S. Manufacturing Capabilities
2+ hour, 23+ min ago (173+ words) Parnell Acquires Noble Pharma LLC, Expanding U.S. Manufacturing Capabilities'BioSpace Parnell Acquires Noble Pharma LLC, Expanding U.S. Manufacturing Capabilities Acquisition adds FDA" and DEA-accredited manufacturing facility to Parnell's operations SYDNEY, Australia--(BUSINESS WIRE)--Parnell today announced the acquisition of Noble Pharma LLC, a…...
Resolve Therapeutics and Institut Pasteur Collaborate to Identify Cell-Free RNA Triggers in Autoimmunity
2+ hour, 36+ min ago (316+ words) Resolve Therapeutics and Institut Pasteur Collaborate to Identify Cell-Free RNA Triggers in Autoimmunity'BioSpace Resolve Therapeutics and Institut Pasteur Collaborate to Identify Cell-Free RNA Triggers in Autoimmunity Resolve Therapeutics and Institut Pasteur de Montevideo today announce a collaboration to use REJOIN-seq…...
AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies
3+ hour, 27+ min ago (320+ words) AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies'BioSpace Humira will be available on TrumpRx at an 86% discount, according to media reports, as part of AbbVie's deal with the White House to avoid tariffs The news comes…...
Biocon Announces U.S. Commercial Launch of Bosaya™ and Aukelso™, Denosumab Biosimilars
2+ hour, 28+ min ago (318+ words) Denosumab products play a critical role in bone health, treating osteoporosis and bone complications associated with cancer. In 2024, denosumab products generated approximately $5 billion in U.S. sales, reflecting the growing need for accessible treatment options. Both biosimilars will be available in the…...
Nexus Pharmaceuticals Launches Cyclophosphamide Injection, 2.5 mL and 5 mL
13+ hour, 53+ min ago (142+ words) LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--#Cyclophosphamide--Nexus Pharmaceuticals, LLC announces the launch of Cyclophosphamide Injection, available in ready to dilute 2.5 mL fill and 5 mL fill multiple-dose vials. As the first AP Rated Generic to Dr. Reddy's, this product provides healthcare providers with…...
Google News
6+ hour, 36+ min ago (12+ words) Gilead Swallows Another Partner, Paying up to $5.3B for ADC Specialist Tubulis'BioSpace...
Section 232 Pharmaceutical Tariffs - Biocom Statement
10+ hour, 45+ min ago (361+ words) Biocom shares the Administration's interest in protecting our country's national security and ensuring that our pharmaceutical supply chain remains strong and stable. However, tariffs on pharmaceutical products and their ingredients will significantly harm domestic drug development and innovation, increase patient…...
UPSHER-SMITH LAUNCHES GENERIC VERSION OF CIPRODEX® (CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1%) STERILE OTIC SUSPENSION
14+ hour, 13+ min ago (132+ words) UPSHER-SMITH LAUNCHES GENERIC VERSION OF CIPRODEX" (CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1%) STERILE OTIC SUSPENSION'BioSpace UPSHER-SMITH LAUNCHES GENERIC VERSION OF CIPRODEX" (CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1%) STERILE OTIC SUSPENSION First Prescription Ear Drop Suspension Advances Portfolio Diversification Strategy "The introduction of Upsher-Smith's first prescription ear…...
ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-Producing Enterobacterales Infections
6+ hour, 24+ min ago (573+ words) Real-world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 83% overall survival at day 28, for patients infected with highly resistant metallo-beta lactamase (MBL)-producing pathogens1 Carbapenem-resistant Enterobacterales pathogens are considered by the World Health Organization to be…...
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
2+ hour, 27+ min ago (306+ words) Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)BioSpace -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in…...